---
title: "Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287223836.md"
description: "Fate Therapeutics, Inc. (NASDAQ: FATE) announced it will present data on its off-the-shelf CAR T-cell therapy pipeline at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, and the EULAR Annual Meeting in London from June 3 to June 6, focusing on iPSC-derived immunotherapies for cancer and autoimmune diseases."
datetime: "2026-05-21T12:33:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287223836.md)
  - [en](https://longbridge.com/en/news/287223836.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287223836.md)
generator: "portal-rs"
---

# Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

On May 21, 2026, Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, revealed plans to showcase data from its off-the-shelf CAR T-cell programs at two upcoming events. The American Society of Cancer Oncology Annual Meeting in Chicago, IL from May 29 to June 2, 2026, and the European Congress of Rheumatology in London, UK from June 3 to June 6, 2026 will host presentations on the company's induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T program](https://longbridge.com/en/news/297902766.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences](https://longbridge.com/en/news/282206169.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**